334 related articles for article (PubMed ID: 35056105)
1. Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies.
Alexander M; Luo Y; Raimondi G; O'Shea JJ; Gadina M
Pharmaceuticals (Basel); 2021 Dec; 15(1):. PubMed ID: 35056105
[TBL] [Abstract][Full Text] [Related]
2. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.
Virtanen A; Palmroth M; Liukkonen S; Kurttila A; Haikarainen T; Isomäki P; Silvennoinen O
Arthritis Rheumatol; 2023 Nov; 75(11):2054-2061. PubMed ID: 37134144
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review.
Jain NK; Tailang M; Jain HK; Chandrasekaran B; Sahoo BM; Subramanian A; Thangavel N; Aldahish A; Chidambaram K; Alagusundaram M; Kumar S; Selvam P
Front Pharmacol; 2023; 14():1135145. PubMed ID: 37021053
[TBL] [Abstract][Full Text] [Related]
4. Hi-
Burja B; Mertelj T; Frank-Bertoncelj M
Front Med (Lausanne); 2020; 7():124. PubMed ID: 32432116
[TBL] [Abstract][Full Text] [Related]
5. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase inhibitors for rheumatoid arthritis.
Yamaoka K
Curr Opin Chem Biol; 2016 Jun; 32():29-33. PubMed ID: 26994322
[TBL] [Abstract][Full Text] [Related]
7. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
Bonelli M; Kerschbaumer A; Kastrati K; Ghoreschi K; Gadina M; Heinz LX; Smolen JS; Aletaha D; O'Shea J; Laurence A
Ann Rheum Dis; 2024 Jan; 83(2):139-160. PubMed ID: 37923366
[TBL] [Abstract][Full Text] [Related]
8. JAK inhibitors: Is specificity at all relevant?
Gadina M
Semin Arthritis Rheum; 2024 Feb; 64S():152327. PubMed ID: 38007359
[TBL] [Abstract][Full Text] [Related]
9. JAK inhibitors: Ten years after.
Spinelli FR; Meylan F; O'Shea JJ; Gadina M
Eur J Immunol; 2021 Jul; 51(7):1615-1627. PubMed ID: 33930196
[TBL] [Abstract][Full Text] [Related]
10. Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
Harigai M; Honda S
Drugs; 2020 Aug; 80(12):1183-1201. PubMed ID: 32681420
[TBL] [Abstract][Full Text] [Related]
11. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
T Virtanen A; Haikarainen T; Raivola J; Silvennoinen O
BioDrugs; 2019 Feb; 33(1):15-32. PubMed ID: 30701418
[TBL] [Abstract][Full Text] [Related]
12. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.
Schwartz DM; Kanno Y; Villarino A; Ward M; Gadina M; O'Shea JJ
Nat Rev Drug Discov; 2017 Dec; 16(12):843-862. PubMed ID: 29104284
[TBL] [Abstract][Full Text] [Related]
13. Janus kinases to jakinibs: from basic insights to clinical practice.
Gadina M; Le MT; Schwartz DM; Silvennoinen O; Nakayamada S; Yamaoka K; O'Shea JJ
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i4-i16. PubMed ID: 30806710
[TBL] [Abstract][Full Text] [Related]
14. Are All Janus Kinase Inhibitors for Inflammatory Bowel Disease the Same?
Honap S; Danese S; Peyrin-Biroulet L
Gastroenterol Hepatol (N Y); 2023 Dec; 19(12):727-738. PubMed ID: 38404416
[TBL] [Abstract][Full Text] [Related]
15. JAK: Not Just Another Kinase.
Agashe RP; Lippman SM; Kurzrock R
Mol Cancer Ther; 2022 Dec; 21(12):1757-1764. PubMed ID: 36252553
[TBL] [Abstract][Full Text] [Related]
16. A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?
Liu C; Kieltyka J; Fleischmann R; Gadina M; O'Shea JJ
Arthritis Rheumatol; 2021 Dec; 73(12):2166-2178. PubMed ID: 34180156
[TBL] [Abstract][Full Text] [Related]
17. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
Fragoulis GE; McInnes IB; Siebert S
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i43-i54. PubMed ID: 30806709
[TBL] [Abstract][Full Text] [Related]
18. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.
Kontzias A; Kotlyar A; Laurence A; Changelian P; O'Shea JJ
Curr Opin Pharmacol; 2012 Aug; 12(4):464-70. PubMed ID: 22819198
[TBL] [Abstract][Full Text] [Related]
19. The Jakinibs in systemic lupus erythematosus: progress and prospects.
Mok CC
Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
[TBL] [Abstract][Full Text] [Related]
20. Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis.
Garufi C; Maclean M; Gadina M; Spinelli FR
Expert Rev Clin Immunol; 2022 Mar; 18(3):309-319. PubMed ID: 35168456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
